OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 64 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Follow-Up Questions
ORPOF hissesinin fiyat performansı nasıl?
ORPOF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
OSE Immunotherapeutics SA için ana iş temaları veya sektörler nelerdir?
OSE Immunotherapeutics SA Biotechnology endüstrisine ait ve sektör Health Care 'dir
OSE Immunotherapeutics SA 'in piyasa değerlemesi nedir?
OSE Immunotherapeutics SA 'in mevcut piyasa değerlemesi $NaN 'dir
OSE Immunotherapeutics SA al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 6 analist OSE Immunotherapeutics SA için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 6 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
